From UBS...
The Plasma Protein Therapeutics Association produces monthly data on plasma distribution volumes in the USA. According to its April figures, CSL’s immunoglobulin (IG) business grew 13.9% (12-month rolling basis). This was slightly up from March’s 13.8%.UBS forecasts a decline in plasma collection of -20% for the April-September period owing to covid-19 induced restrictions. This in turn reduces forecasts for IG/albumin volumes by -20% for the first half of FY21.The broker highlights every -5% reduction in plasma collections over a 6-month period translates to a circa -2% earnings downgrade for the year.The company will be releasing its FY20 results on August 19.UBS retains its Buy rating with a target price of $331.
- Forums
- ASX - By Stock
- Short CSL ? HCQ is the Cure
From UBS...The Plasma Protein Therapeutics Association produces...
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CSL (ASX) to my watchlist
|
|||||
Last
$303.99 |
Change
0.890(0.29%) |
Mkt cap ! $147.1B |
Open | High | Low | Value | Volume |
$302.12 | $305.00 | $300.79 | $155.5M | 515.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 330 | $303.79 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$304.25 | 386 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100 | 302.840 |
1 | 2 | 301.750 |
1 | 100 | 301.380 |
1 | 2 | 301.000 |
1 | 55 | 300.980 |
Price($) | Vol. | No. |
---|---|---|
304.650 | 70 | 1 |
304.810 | 21 | 1 |
305.000 | 2004 | 17 |
305.010 | 285 | 1 |
305.100 | 35 | 1 |
Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
Featured News
CSL (ASX) Chart |